Recently, Jiangsu Hansoh Pharmaceutical Group Co., Ltd. ("Hansoh Pharma" or the "Company") won the honorary title of "Science and Technology Innovation and Development Award in Jiangsu Province - Excellent Enterprise" in the first session for its R&D strength and outstanding achievements in the field of science and technology innovation. 

The Science and Technology Innovation and Development Award in Jiangsu Province is granted by the People's Government of Jiangsu Province, aiming to commend the organizations, businesses and individuals that have achieved excellent results in organizing and promoting science and technology innovation, made breakthroughs in important fields or major projects, delivered remarkable results in innovation and development, and contributed significantly to promoting science and technology innovation in other fields. The winners will be selected once every two years. 

Hansoh Pharma always regards science and technology innovation as the core driving force for high-quality development. After more than 20 years of high-intensity R&D investment, the Company has established R&D centers in Shanghai, Lianyungang and other places, with its focus on innovative R&D in the treatment of major diseases such as oncology, CNS, anti-infectives and diabetes, and has been ranked top 30 among China's Top 100 Companies in Pharmaceutical Industry and top 3 among China's Best Industrial Enterprises in Pharmaceutical R&D Pipeline for consecutive years. It's also a national key high-tech enterprise and a national technology innovation demonstration enterprise. Up to now, Hansoh Pharma has marketed four Class 1 innovative drugs; and Hengmu (Tenofovir Amibufenamide Fumarate Tablets), China's first original oral Class 1 new drug for the treatment of hepatitis B, will also be approved for marketing in the near future. 

Hansoh Pharma attaches great importance to building and raising innovation awareness, adopts an innovation approach in its management, operation, technology and all other aspects, adapts to market changes, promotes transformation and upgrading, and keeps improving its core competitiveness and brand influence. Upholding the corporate mission to "create excellence in pharmaceuticals, enhance innovation in China", and staying “focused, dedicated and professional”, the Company strives to develop more innovative drugs and thereby improve human health and quality of life.